{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:27:24Z","timestamp":1787120844919,"version":"build-2736575974"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cyclin-dependent kinase 4 and 6 (CDK4\/6) inhibitors are standard endocrine-based treatments for hormone receptor-positive (HR-positive), HER2-negative breast cancer, but drug-specific adverse event reporting patterns differ among agents. This study prioritized adverse events of special interest (AESIs) for palbociclib, abemaciclib, and ribociclib using the Food and Drug Administration Adverse Event Reporting System (FAERS), exploratory machine learning (ML), and institutional clinical contextualization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Primary suspect FAERS reports from 2015Q1 to 2025Q4 were analyzed at the report level. Reports were mapped to eight AESI domains and assessed using disproportionality measures, intraclass-adjusted reporting odds, reported time to onset, and exploratory ML signal prioritization. ML models were developed using data from 2015Q1 to 2022Q4 and temporally validated using data from 2023Q1 to 2025Q4. Consecutive patients treated at a Chinese tertiary cancer center between 6 January 2023 and 29 December 2024 were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>FAERS included 115,971 class-wide primary suspect reports and 67,314 reports with breast cancer recorded as the indication. The three-agent ML dataset included 115,771 reports, with 76,581 for model development and 39,190 for temporal validation. Palbociclib was characterized mainly by hematologic reporting; abemaciclib by gastrointestinal, thrombotic, pulmonary, and renal- or creatinine-related prioritization; and ribociclib by QT interval and hepatobiliary prioritization. The institutional cohort included 82 patients and contextualized these AESIs through treatment-emergent events, grade 3 or higher toxicity, dose modification, and temporal clinical consequence markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The three agents showed distinct report-level safety reporting profiles. These findings prioritize drug-specific AESIs for pharmacovigilance review and safety hypothesis generation; however, incidence, causal effects, and patient-level risk estimation require denominator-based clinical datasets.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1889178","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:45:30Z","timestamp":1787118330000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative safety signal prioritization of CDK4\/6 inhibitors in breast cancer: a FAERS pharmacovigilance, machine learning, and clinical contextualization study"],"prefix":"10.3389","volume":"17","author":[{"given":"Linlin","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin Medical University","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaochun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin Medical University","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin Medical University","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin Medical University","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin Medical University","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin Medical University","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqi","family":"Sui","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin Medical University","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin Medical University","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s40264-023-01317-0","article-title":"Developing an artificial intelligence-guided signal detection in the food and drug administration adverse event reporting system (FAERS): a proof-of-concept study using galcanezumab and simulated data","volume":"46","author":"Al-Azzawi","year":"2023","journal-title":"Drug Saf."},{"key":"B2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40264-024-01430-8","article-title":"Timing matters: a machine learning method for the prioritization of drug-drug interactions through signal detection in the FDA adverse event reporting system and their relationship with time of Co-exposure","volume":"47","author":"Battini","year":"2024","journal-title":"Drug Saf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","article-title":"FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-Negative metastatic breast cancer","volume":"21","author":"Beaver","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"104290","DOI":"10.1016\/j.esmoop.2025.104290","article-title":"Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer","volume":"10","author":"Buijs","year":"2025","journal-title":"ESMO Open"},{"key":"B5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41416-021-01415-9","article-title":"Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"125","author":"Burris","year":"2021","journal-title":"Br. J. Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10238-024-01458-1","article-title":"Real-world experience with CDK4\/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population","volume":"24","author":"Chen","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jclinepi.2019.02.004","article-title":"A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models","volume":"110","author":"Christodoulou","year":"2019","journal-title":"J. Clin. Epidemiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"B9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2023","journal-title":"Front. Drug Saf. Regul."},{"key":"B11","doi-asserted-by":"publisher","first-page":"20420986231219472","DOI":"10.1177\/20420986231219472","article-title":"Evaluation of four machine learning models for signal detection","volume":"14","author":"Dauner","year":"2023","journal-title":"Ther. Adv. Drug Saf."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1634\/theoncologist.2019-0019","article-title":"Palbociclib with letrozole in postmenopausal women with ER+\/HER2- advanced breast cancer: hematologic safety analysis of the randomized PALOMA-2 trial","volume":"24","author":"Di\u00e9ras","year":"2019","journal-title":"Oncologist"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/14740338.2023.2181338","article-title":"Thromboembolism profiles associated with cyclin-dependent kinase 4\/6 inhibitors: a real-world pharmacovigilance study and a systematic review","volume":"22","author":"Gao","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO-25-00167","article-title":"US food and drug administration approval summary: ribociclib with an aromatase inhibitor in the adjuvant hormone receptor-positive, human epidermal growth factor receptor 2-Negative stage II and III high-risk early breast cancer treatment setting","volume":"43","author":"Gao","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40264-023-01302-7","article-title":"Factors associated with underreporting of adverse drug reactions by health care professionals: a systematic review update","volume":"46","author":"Garc\u00eda-Abeijon","year":"2023","journal-title":"Drug Saf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1002\/pds.5553","article-title":"Development of a multivariate prediction model to identify individual case safety reports which require clinical review","volume":"31","author":"Gosselt","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B19","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40264-024-01433-5","article-title":"Comparators in pharmacovigilance: a quasi-quantification bias analysis","volume":"47","author":"Gravel","year":"2024","journal-title":"Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-Positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"102827","DOI":"10.1016\/j.ctrv.2024.102827","article-title":"Abemaciclib increases the risk of venous thromboembolism in breast cancer: integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation","volume":"130","author":"Hua","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-Node-Positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/bcp.15024","article-title":"Numbers of spontaneous reports: how to use and interpret?","volume":"88","author":"Kant","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40360-024-00770-6","article-title":"Comparative analysis of adverse events associated with CDK4\/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study","volume":"25","author":"Lin","year":"2024","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e082505","DOI":"10.1136\/bmj-2024-082505","article-title":"PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods","volume":"388","author":"Moons","year":"2025","journal-title":"BMJ"},{"key":"B29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/14737140.2021.1852934","article-title":"CDK4\/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis","volume":"21","author":"Onesti","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/14740338.2024.2387323","article-title":"A disproportionality analysis of CDK4\/6 inhibitors in the FDA adverse event reporting system (FAERS)","volume":"24","author":"Peng","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1269922","DOI":"10.3389\/fphar.2024.1269922","article-title":"The adverse events of CDK4\/6 inhibitors for HR+\/HER2-breast cancer: an umbrella review of meta-analyses of randomized controlled trials","volume":"15","author":"Pu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/JCO.23.01994","article-title":"Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-Negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-Year efficacy outcomes","volume":"42","author":"Rastogi","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1200\/JCO.21.02742","article-title":"FDA approval summary: abemaciclib with endocrine therapy for high-risk early breast cancer","volume":"40","author":"Royce","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1158\/1078-0432.CCR-17-2369","article-title":"FDA approval: ribociclib for the treatment of postmenopausal women with hormone receptor-positive, HER2-Negative advanced or metastatic breast cancer","volume":"24","author":"Shah","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s40264-023-01334-z","article-title":"Disproportionality analysis of abemaciclib in the FDA adverse event reporting system: a real-world post-marketing pharmacovigilance assessment","volume":"46","author":"Shu","year":"2023","journal-title":"Drug Saf."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-Negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2025.2468357","article-title":"Hepatic adverse events with CDK4\/6 inhibitors: a systematic review combining meta-analysis and FAERS database","author":"Tang","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"B41","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1634\/theoncologist.2016-0097","article-title":"Palbociclib in combination with fulvestrant in women with hormone Receptor-Positive\/HER2-Negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3)","volume":"21","author":"Verma","year":"2016","journal-title":"Oncologist"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1080\/14740338.2024.2307375","article-title":"A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4\/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting system","volume":"23","author":"Yan","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B45","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S1470-2045(23)00172-9","article-title":"Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"24","author":"Zhang","year":"2023","journal-title":"Lancet Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"17588359241286775","DOI":"10.1177\/17588359241286775","article-title":"Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2-high-risk early breast cancer: 5-Year Chinese population analysis of the phase III randomized monarchE study","volume":"16","author":"Zhang","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1007\/s12325-026-03538-y","article-title":"A retrospective observational study of safety and effectiveness of abemaciclib in Chinese patients with breast cancer","volume":"43","author":"Zhao","year":"2026","journal-title":"Adv. Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11523-020-00771-5","article-title":"Impact of dose reduction on efficacy: implications of exposure-response analysis of palbociclib","volume":"16","author":"Zheng","year":"2021","journal-title":"Target Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"103160","DOI":"10.1016\/j.eclinm.2025.103160","article-title":"Disproportionality analysis of interstitial lung disease associated with novel antineoplastic agents during breast cancer treatment: a pharmacovigilance study","volume":"82","author":"Zhu","year":"2025","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1889178\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:45:31Z","timestamp":1787118331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1889178\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":49,"alternative-id":["10.3389\/fphar.2026.1889178"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1889178","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1889178"}}